Epithalon — compound monograph
Synthetic tetrapeptide. Unapproved, research supply. The Institute assesses 3 outcomes for this compound and grades the strongest at very low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- Epithalon
- Compound class
- Synthetic tetrapeptide
- Assessment series
- Neuroactive peptides
- Synonyms and codes
- epitalon · AEDG peptide · Ala-Glu-Asp-Gly · epithalamin tetrapeptide
- Route as evaluated
- Subcutaneous, intramuscular or intranasal in research contexts
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 307297-39-8
- Molecular formula
- C14H22N4O9
- Average mass
- 390.35
- Monoisotopic mass
- 390.14
- ATC classification
- not assigned
§1.3Sequence and structural notes
A tetrapeptide developed as a synthetic analogue of the pineal extract epithalamin. It is one of the shortest peptides in this series and its brevity makes conventional reverse-phase purity determination genuinely difficult.
§1.4Assessment status
The Institute assesses Epithalon across 3 indications and grades the strongest of them at very low certainty. Supplied as a research chemical; no marketing authorisation for the uses under which it is supplied.
Table 1. Assessed outcomes for Epithalon, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Biological ageing and healthspan endpoints | Russian observational and small controlled reports describe mortality and functional differences over multi-year follow-up | Very low | 1 |
| Cognitive performance and neuroprotection | No assessable evidence identified | Very low | 0 |
| Immune modulation and adjunctive immunotherapy | No assessable evidence identified | Very low | 0 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.